Lu Victor M, Alvi Mohammed Ali, Bydon Mohamad, Quinones-Hinojosa Alfredo, Chaichana Kaisorn L
Department of Neurosurgery, Mayo Clinic, Rochester, MN, USA.
Department of Neurosurgery, Mayo Clinic, Rochester, MN, USA.
Clin Neurol Neurosurg. 2019 Jul;182:32-36. doi: 10.1016/j.clineuro.2019.04.027. Epub 2019 Apr 30.
Traditionally, extent of resection (EOR) has been seen as a surgical parameter that can predict survival outcomes of surgically managed WHO grade II gliomas. The aim of this study was to evaluate if such an influence was potentially affected by 1p/19q codeletion status based on a national cancer registry.
All adults diagnosed with grade II gliomas between the years 2004 to 2014 were queried from the National Cancer Database (NCDB). The population was then divided based on 1p/19q codeletion status, and then Kaplan-Meier, univariate and multivariate Cox regression analyses were utilized to evaluate the prognostic effect of EOR.
In total, 1,498 grade II gliomas satisfied inclusion for analysis, with the 1p/19q non-codeleted in 705 (47%) cases, and codeletion in 793 (53%) cases. When the cohort was divided based on codeletion status, Kaplan-Meier modelling and univariate regression analyses indicated that gross total resection (GTR) was significantly associated with greater 5-overall survival (OS) in both 1p/19q non-codeleted and codeletion groups. Upon multivariate analysis which incorporated adjuvant therapy status, the significance of GTR was only retained in the 1p/19q non-codeletion group after post-hoc adjustment.
Our findings indicate that the survival impact of GTR in grade II gliomas may be affected by 1p/19q codeletion status within the first five years after surgery based on overall survival. Therefore, molecular diagnostics have potential clinical application in surgery outcomes, and validation of the reported findings will assist in surgical planning if such an association can be thoroughly established.
传统上,切除范围(EOR)被视为一个手术参数,可预测接受手术治疗的世界卫生组织二级胶质瘤的生存结果。本研究的目的是基于国家癌症登记处评估这种影响是否可能受1p/19q共缺失状态的影响。
从国家癌症数据库(NCDB)中查询2004年至2014年间所有诊断为二级胶质瘤的成年人。然后根据1p/19q共缺失状态对人群进行划分,接着采用Kaplan-Meier法、单因素和多因素Cox回归分析来评估EOR的预后效果。
共有1498例二级胶质瘤符合纳入分析标准,其中705例(47%)为1p/19q非共缺失,793例(53%)为共缺失。当根据共缺失状态对队列进行划分时,Kaplan-Meier建模和单因素回归分析表明,在1p/19q非共缺失组和共缺失组中,大体全切(GTR)均与更好的5年总生存期(OS)显著相关。在纳入辅助治疗状态的多因素分析中,经过事后调整后,GTR的显著性仅在1p/19q非共缺失组中得以保留。
我们的研究结果表明,基于总生存期,GTR对二级胶质瘤生存的影响可能在术后头五年内受1p/19q共缺失状态的影响。因此,分子诊断在手术结果方面具有潜在的临床应用价值,如果这种关联能够得到充分确立,对所报告结果的验证将有助于手术规划。